Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform ...

Citi initiated coverage of Avidity Biosciences (RNA) with a Buy rating and $70 price target Healthcare policy remains a key biopharma sector ...

Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, ...

BMO Capital initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $72 price target Avidity’s pipeline includes ...

Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (oral presentation) Aravindhan Veerapandiyan, MD ...

Avidity Biosciences, Inc. (NASDAQ:RNA) has emerged as a frontrunner in the development of RNA-based therapies, leveraging its proprietary antibody-oligonucleotide conjugate (AOC) platform to ...

NASDAQ RNA opened at $30.04 on Monday. The firm has a market capitalization of $3.61 billion, a P/E ratio of -10.43 and a beta of 1.02. Avidity Biosciences has a 1-year low of $20.80 and a 1-year ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform recommendation. As of March 5, 2025, the average one-year price target ...

Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and ...

On Tuesday, BMO Capital Markets began coverage of Avidity Biosciences (NASDAQ:RNA) shares, assigning an Outperform rating and setting a price target of $72.00. Currently trading at $29.58, the stock ...